TherapeuticsMD, Inc. (TXMD)

NASDAQ: TXMD · USD

$1.76

-0.02 (-1.1%)· Recorded snapshot

Market cap	20.4M
Revenue (ttm)	3.3M
Net income (ttm)	-217K
EPS (ttm)	-$0.02
Shares out	11.6M
Volume	21,848
Beta	0.65

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 3.3M
Net income (ttm): -217K
EPS (ttm): -$0.02
Market cap: 20.4M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-1.1

P25 -113.8P50 -46.5P75 -0.9

ROIC-7.3

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All TXMD indicators

Market & fundamental data

Available fields

222

Groups with data

Currency

USD

Showing 222 of 222 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000025743
Company name	TherapeuticsMD, Inc.
Country	United States
Country code	US
CUSIP number	88338N206
Earnings date	2026-11-11
Earnings time	amc
Employees	1
Employees change	0
Employees growth	0%
Enterprise value	$16.7M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2008
Industry	Drug Manufacturers - Specialty & Generic
Is primary listing	Yes
Is SPAC	No
ISIN number	US88338N2062
Last 10-K release date	2026-03-30
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split date	2022-05-09
Last stock split type	Reverse
Market cap	$20.4M
Market cap category	Nano-Cap
Next earnings date	2026-11-11
Options	Yes
Price	$1.76
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	TXMD
U.S. state	Florida
Website	https://www.therapeuticsmd.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-1.31%
EV/FCF	5.44x
EV/Sales	5.19x
FCF / EV yield	18.38%
FCF yield	15.14%
Industry forward P/E	13.59x
Industry P/E	175.96x
P/(FCF - SBC) ratio	6.73x
P/(OCF - SBC) ratio	6.73x
P/B ratio	0.76x
P/FCF ratio	6.6x
P/OCF ratio	6.6x
P/S ratio	6.3x
Price / tangible book value	0.87x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-53.55%
EBITDA margin	-41.87%
FCF margin	95.41%
Gross margin	100%
Operating margin	-53.55%
Pretax margin	-8.04%
Profit margin	-6.64%
Profit per employee	$-217,000
Profitable quarters	2
Revenue per employee	$3.3M
ROA	-2.88%
ROA (5Y)	-7.5%
ROCE	-5.38%
ROE	-1.08%
ROIC	-7.31%
SBC / revenue	1.74%
Tax / revenue	0.98%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth (Q)	-80.62%
EPS growth (QoQ)	12.41%
EPS growth years	2
FCF growth	272.76%
FCF growth (Q)	137.65%
FCF growth (QoQ)	-17.74%
Gross profit growth	27.78%
Gross profit growth (Q)	-8.72%
Gross profit growth 3Y	-63.88%
Gross profit growth 5Y	-45.35%
Net income growth (Q)	-71.87%
Net income growth (QoQ)	63.16%
Net income growth years	2
OCF growth	272.76%
OCF growth (Q)	137.65%
OCF growth (QoQ)	-17.74%
Revenue growth	27.78%
Revenue growth (Q)	-8.72%
Revenue growth (QoQ)	20.03%
Revenue growth 10Y	-16.63%
Revenue growth 3Y	-63.95%
Revenue growth 5Y	-47.85%
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$382,000
EBIT	$-1.8M
EBITDA	$-1.4M
EPS	$-0.02
FCF per share	$0.27
Free cash flow	$3.1M
Free cash flow minus SBC	$3.1M
Gross profit	$3.3M
Income taxes	$32,000
Net cash flow	$3.1M
Net income	$-217,000
Operating cash flow minus SBC	$3.1M
Operating income	$-1.8M
Revenue	$3.3M
Stock-based compensation	$57,000

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-34.09
Book value per share	$2.34
Debt / equity	0.2
Debt / FCF	1.78
Long-term assets	$21.4M
Long-term liabilities	$5.4M
Net cash (debt)	$3.6M
Net cash / market cap	17.61%
Net debt / equity	-0.13
Net debt / FCF	-1.16
Piotroski F-Score	4
Property, plant and equipment	$4.8M
Shareholders' equity	$27.1M
Tangible book value	$23.6M
Tangible book value per share	$2.04
Total assets	$37.5M
Total cash	$9.2M
Total debt	$5.6M
Total liabilities	$10.4M
WACC	6.16%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.09
Current assets	$16.1M
Current liabilities	$5M
Current ratio	3.22
Net working capital	$3M
Quick ratio	2.65
Working capital	$11.1M
Working capital turnover	0.33

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.23%
Dividend yield	0%
Shareholder yield	-0.23%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-99.39%
10Y return CAGR	-39.97%
10Y total return	-99.39%
150-day SMA	$2.06
1D price change	-1.12%
1M price change	-13.17%
1M total return	-13.17%
1W price change	-5.32%
1W total return	-5.32%
1Y price change	35.88%
1Y return CAGR	35.91%
1Y total return	35.88%
20-day SMA	$1.93
200-day SMA	$2.12
3M price change	-14.01%
3M total return	-14.01%
3Y price change	-11.44%
3Y return CAGR	-3.97%
3Y total return	-11.44%
50-day SMA	$2.06
50-day SMA vs 200-day SMA	50under200
52-week high	$2.95
52-week high date	2026-01-27
52-week low	$1.11
52-week low date	2025-11-05
5Y price change	-95.19%
5Y return CAGR	-45.5%
5Y total return	-95.19%
6M price change	-14.01%
6M total return	-14.01%
All-time high	$563.00
All-time high date	2015-12-29
All-time low	$0.70
All-time low date	2024-12-31
Average true range (ATR)	$0.07
Average volume	21.1K
Beta (1Y)	0.08
Beta (2Y)	1.08
Beta (5Y)	0.65
Change from 52-week high	-40.34%
Change from 52-week low	58.56%
Change from all-time high	-99.68%
Change from all-time low	154.29%
Change from open	0%
Day's gap	-1.12%
Dollar volume	$38,452
High price	$1.76
Low price	$1.75
Monthly RSI	38.44
Open price	$1.76
Position in 52-week range	100%
Premarket change	-1.12%
Premarket close	$1.78
Premarket price	$1.76
Previous close	$1.78
Price vs 150-day SMA	-13.55%
Price vs 20-day SMA	-7.77%
Price vs 200-day SMA	-16%
Price vs 50-day SMA	-13.63%
Relative volume	1.04
RSI	27.26
Sharpe ratio	0.72
Sharpe ratio (3Y)	0.25
Sharpe ratio (5Y)	0.1
Sortino ratio	1.26
Sortino ratio (3Y)	0.55
Sortino ratio (5Y)	0.39
Volume	21.8K
Weekly RSI	37.24
YTD price change	9.2%
YTD total return	9.2%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	9.5M
Float percentage	82.01%
Shares change (QoQ)	0.03%
Shares change (YoY)	0.23%
Shares held by insiders	2.2%
Shares held by institutions	22.72%
Shares outstanding	11.6M
Short % of float	0.25%
Short % of shares	0.2%
Short ratio	1.2 days

Deeper analysis on TXMD

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this TXMD report

Is a complete TXMD research report available?

No complete published report is available for TherapeuticsMD, Inc. (TXMD) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

TherapeuticsMD, Inc. (TXMD)

Price

Financial snapshot

Fair-value bridge

Latest news · TXMD

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All TXMD indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on TXMD

Frequently asked questions